JP2012510280A5 - - Google Patents

Download PDF

Info

Publication number
JP2012510280A5
JP2012510280A5 JP2011539008A JP2011539008A JP2012510280A5 JP 2012510280 A5 JP2012510280 A5 JP 2012510280A5 JP 2011539008 A JP2011539008 A JP 2011539008A JP 2011539008 A JP2011539008 A JP 2011539008A JP 2012510280 A5 JP2012510280 A5 JP 2012510280A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
derivative
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011539008A
Other languages
English (en)
Japanese (ja)
Other versions
JP5863458B2 (ja
JP2012510280A (ja
Filing date
Publication date
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed filed Critical
Priority claimed from PCT/EP2009/066201 external-priority patent/WO2010069765A1/en
Publication of JP2012510280A publication Critical patent/JP2012510280A/ja
Publication of JP2012510280A5 publication Critical patent/JP2012510280A5/ja
Application granted granted Critical
Publication of JP5863458B2 publication Critical patent/JP5863458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011539008A 2008-12-02 2009-12-02 新規な抗cMET抗体 Active JP5863458B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
IBPCT/IB2008/055663 2008-12-02
US18450209P 2009-06-05 2009-06-05
US61/184,502 2009-06-05
PCT/EP2009/066201 WO2010069765A1 (en) 2008-12-02 2009-12-02 ANTI-cMET ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015244007A Division JP6074018B2 (ja) 2008-12-02 2015-12-15 新規な抗cMET抗体

Publications (3)

Publication Number Publication Date
JP2012510280A JP2012510280A (ja) 2012-05-10
JP2012510280A5 true JP2012510280A5 (https=) 2013-01-24
JP5863458B2 JP5863458B2 (ja) 2016-02-16

Family

ID=41693124

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011539008A Active JP5863458B2 (ja) 2008-12-02 2009-12-02 新規な抗cMET抗体
JP2015244007A Active JP6074018B2 (ja) 2008-12-02 2015-12-15 新規な抗cMET抗体
JP2017000641A Active JP6309657B2 (ja) 2008-12-02 2017-01-05 新規な抗cMET抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015244007A Active JP6074018B2 (ja) 2008-12-02 2015-12-15 新規な抗cMET抗体
JP2017000641A Active JP6309657B2 (ja) 2008-12-02 2017-01-05 新規な抗cMET抗体

Country Status (38)

Country Link
US (4) US8741290B2 (https=)
EP (4) EP3431502B1 (https=)
JP (3) JP5863458B2 (https=)
KR (1) KR101838299B1 (https=)
CN (2) CN103351438B (https=)
AR (1) AR074439A1 (https=)
AU (3) AU2009328318C1 (https=)
BR (2) BR122019023930B1 (https=)
CA (1) CA2743433C (https=)
CL (2) CL2011001296A1 (https=)
CO (1) CO6382139A2 (https=)
CR (1) CR20110324A (https=)
CY (2) CY1119172T1 (https=)
DK (2) DK3135691T3 (https=)
EC (1) ECSP11011127A (https=)
ES (3) ES2827277T3 (https=)
GE (2) GEP20135930B (https=)
HR (2) HRP20171011T8 (https=)
HU (3) HUE040553T2 (https=)
IL (2) IL213273A0 (https=)
LT (2) LT2370468T (https=)
MA (1) MA32892B1 (https=)
MX (2) MX2011005677A (https=)
MY (2) MY185200A (https=)
NZ (1) NZ593853A (https=)
PE (1) PE20120343A1 (https=)
PH (1) PH12015501515A1 (https=)
PL (3) PL2370468T3 (https=)
PT (3) PT2370468T (https=)
RS (2) RS56204B1 (https=)
RU (2) RU2015127471A (https=)
SA (2) SA109300720B1 (https=)
SG (2) SG171851A1 (https=)
SI (3) SI3431502T1 (https=)
TN (1) TN2011000216A1 (https=)
TW (2) TWI523866B (https=)
WO (1) WO2010069765A1 (https=)
ZA (1) ZA201105164B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
KR20140019284A (ko) 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 c-Met 인간화 항체 및 그의 용도
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 c-Met에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
CN105050618B (zh) * 2012-06-21 2018-11-16 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN105452297B (zh) 2013-04-30 2019-10-11 新加坡科技研究局 mAb 2抗-Met抗体
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
KR102476846B1 (ko) * 2016-02-05 2022-12-12 주식회사 헬릭스미스 항―c―MET 항체 및 이의 용도
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
SI3626273T1 (sl) 2016-05-17 2021-04-30 Abbvie Biotherapeutics Inc. Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
KR102835308B1 (ko) * 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US20220169706A1 (en) * 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
BR112023020562A2 (pt) 2021-04-06 2023-12-05 Abbvie Biotherapeutics Inc Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina
BR112023020801A2 (pt) * 2021-04-08 2023-12-12 Byondis Bv Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica
TW202547842A (zh) * 2021-04-29 2025-12-16 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023173109A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib
WO2024243450A1 (en) 2023-05-23 2024-11-28 Abbvie Inc. Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
KR100983997B1 (ko) * 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP2397498A3 (en) * 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー M−csf特異的モノクローナル抗体およびその使用
US8101727B2 (en) * 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Similar Documents

Publication Publication Date Title
JP2012510280A5 (https=)
CN110914306B (zh) 检查点抑制物双特异性抗体
AU2016315892B2 (en) Compositions and methods for modulating T-cell mediated immune response
KR102357312B1 (ko) Cd20 결합 분자 및 그의 용도
JP2010532982A5 (https=)
JP5769969B2 (ja) Axl抗体
TWI564306B (zh) 雙特異性抗體
RU2011124751A (ru) Антитело против смет
JP2022084608A (ja) 抗trop2抗体-薬物コンジュゲート
CN102421802B (zh) 人源化的axl抗体
JP2012504401A5 (https=)
JP2022515487A (ja) クローディン18.2結合部分およびその利用
RU2451689C2 (ru) Новые антипролиферативные антитела
JP2023106392A (ja) Cd3抗原結合性断片及びその使用
HRP20150887T1 (hr) Nova antitijela koja inhibiraju dimerizaciju c-met te njihova upotreba
JP2010509931A5 (https=)
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
JPWO2002094880A1 (ja) 抗trail−r抗体
WO2023206350A1 (en) Anti-ccr8 antibodies and uses thereof
JP2013056885A5 (https=)
KR20180054590A (ko) 항글리피칸-3 항체 및 이의 응용
JP2011505120A5 (https=)
RU2012145232A (ru) Гуманизированные антитела к cxcr4 для лечения рака
CN102939305A (zh) 对cd122的抗体
WO2011103700A1 (zh) 一种全人源抗her2单克隆抗体、其制备方法及用途